Market Cap (In USD)
423.01 Million
Revenue (In USD)
88.17 Million
Net Income (In USD)
35.63 Million
Avg. Volume
222.00
- Currency
- USD
- Country
- Healthcare
- Open
- -
- Prev. Close
- -
- Day Range
- -
- Year Range
- 8.38-11.55
- PE
- -
- EPS
- -
- Beta Value
- 0.853
- ISIN
- AU000000CUV3
- CUSIP
- -
- CIK
- 1290877
- Shares
- -
- Earnings Annoncement
- -
Company Profile
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Dr. Philippe Jacques Wolgen M.B.A., M.D.
- Employee Count
- -
- Website
- https://www.clinuvel.com
- Ipo Date
- 2009-02-13
- Details
- Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). The company's pipeline products include CUV9900, an alpha-melanocyte stimulating hormone analogue; Parvysmelanotide (VLRX001), which provoke increased and prolonged cellular activity; and PRÉNUMBRA, a liquid injectable formulation of afamelanotide. Clinuvel Pharmaceuticals Limited has a collaboration agreement with HK Winhealth Pharma Group Co. Limited t to treat EPP patients with SCENESSE under a named patient program in the People's Republic of China. The company was founded in 1987 and is headquartered in Melbourne, Australia.
More Stocks
-
RNUGFReNeuron Group plc
RNUGF
-
CVX
-
JPDYYJapan Display Inc.
JPDYY
-
VOXX
-
002674
-
8848
-
USFD
-
6902Gogolook Co., Ltd.
6902